Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign in or Register to read more
19074
19390
Related Questions
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
When is the best time to try targeted therapy in adult-type diffuse non-IDH glioma?
Do you send only serum paraneoplastic panels or also include CSF evaluation in patients with concern for paraneoplastic neuropathy?
How do you evaluate a patient with MGUS and peripheral neuropathy?
How do you approach maintenance immunosuppression in juvenile myasthenia gravis?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
What infections should we rule out in patients who develop diarrhea on immunotherapy?
How do you reconcile the benefits of high glycemic load to slow ALS disease progression with previous data on the increased risk for ALS associated with diabetes mellitus?
How do you counsel patients who wish to travel to high altitudes with myasthenia gravis?